SCHEMBL513371

SCHEMBL513371

C=COBO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL20489372 0.85
SCHEMBL2251688 0.83
SCHEMBL127445 0.67
Vinyl Ether SCHEMBL406230 0.64
SCHEMBL622200 0.62
SCHEMBL932289 0.61
Propene SCHEMBL22609030 0.59
SCHEMBL12126904 0.57
SCHEMBL15740691 0.57
SCHEMBL1230912 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260086097-A1 N-TERMINAL MULTIFUNCTIONAL CONJUGATION OF PROTEINS AND PEPTIDES (FOR BIOSENSING) Roswell Biotechnologies, Inc. (US) 2026-03-26 US claimed
EP-4584585-A2 N-TERMINAL MULTIFUNCTIONAL CONJUGATION OF PROTEINS AND PEPTIDES FOR BIOSENSING Roswell ME Inc. (US) 2025-07-16 EP claimed
WO-2024054632-A2 N-TERMINAL MULTIFUNCTIONAL CONJUGATION OF PROTEINS AND PEPTIDES FOR BIOSENSING Roswell ME Inc. (US) 2024-03-14 WO claimed
CN-117417387-A Synthesis method of nucleoside analogue 苏州翔实医药发展有限公司 2024-01-19 CN claimed
WO-2023195929-A2 BENCH-STABLE SULFONES AS GLYCOSYL DONORS FOR CARBOHYDRATE SYNTHESIS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-10-12 WO claimed
CN-112225729-A Pyrimidine derivative, preparation method and application thereof and pharmaceutical composition 四川大学华西医院 2021-01-15 CN claimed
US-20100228028-A1 PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES ASTRAZENECA UK LIMITED (GB) 2010-09-09 US claimed
EP-1904456-A1 PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES AstraZeneca UK Limited (GB) 2008-04-02 EP claimed
WO-2007007119-A1 PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES ASTRAZENECA UK LIMITED (GB) 2007-01-18 WO claimed
EP-4746911-A1 PHOSPHORAMIDITE LINKERS United Kingdom Research and Innovation (GB) 2026-05-27 EP disclosed
US-12600698-B2 Kinase inhibitors VIDYA THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
US-20260092040-A1 SYNTHESIS OF CYCLOPROPANE CARBOXYLIC ACIDS PAPAIOANNOU NIKOLAOS (US) 2026-04-02 US disclosed
US-20260086097-A1 N-TERMINAL MULTIFUNCTIONAL CONJUGATION OF PROTEINS AND PEPTIDES (FOR BIOSENSING) Roswell Biotechnologies, Inc. (US) 2026-03-26 US disclosed
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 US disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 EP disclosed
US-6222048-B1 AS ANTIINFLAMMATORY, ANTIPYRETIC AND ANALGESIC AGENTS; INHIBITS HORMONE INDUCED UTERINE CONTRACTION; ANTICANCER PROPERTIES; SIDE EFFECT REDUCTION MERCK FROSST CANADA & CO. (CA) 2001-04-24 US disclosed
WO-2001007407-A1 LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-02-01 WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed
EP-0799218-A1 DIARYL-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-10-08 EP disclosed
WO-1996019469-A1 DIARYL-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1996-06-27 WO disclosed